GlassScriptPhysician profile
Peter Joseph Licata
NPI 1336225747
$2,776.36
in general payments reported to CMS, 2019-2025
27 companies · $559 in 2025
The $559 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $136 · 2021: $505 · 2022: $410 · 2023: $400 · 2024: $469 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.09 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $471.56 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $463.33 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $445.09 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $290.46 | 2022-2025 | |
| Amgen INC. | $185.68 | 2021-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $173.34 | 2019-2023 | Veozah |
| Novo Nordisk INC | $100.46 | 2021-2025 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $92.29 | 2019-2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $83.86 | 2021-2023 | |
| Allergan, INC. | $64.98 | 2019-2020 | |
| Edwards Lifesciences Corporation | $38.57 | 2021 | |
| Merck Sharp & Dohme LLC | $38.15 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.69 | 2024-2025 | Caplyta |
| Abbvie INC. | $35.28 | 2021-2025 | |
| Abbott Laboratories | $32.96 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $29.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.42 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $23.03 | 2022 | |
| Horizon Therapeutics Plc | $19.40 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.12 | 2022 | |
| Phadia US INC. | $17.07 | 2025 | Immunocap |
| Ibsa Pharma INC. | $17.05 | 2022 | |
| Opko Pharmaceuticals, LLC | $16.68 | 2019 | |
| Lilly USA, LLC | $16.21 | 2023 | Jardiance |
| Biogen, INC. | $15.10 | 2019 | |
| Bardy Diagnostics, INC. | $13.72 | 2021 | |
| Lucid Diagnostics INC. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Licata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.